This inventor holds 3 USPTO granted patents. Top assignee: The United States of America as Represented by the United States. Active years: 1988.
Company Filing History:
Years Active: 1988
Title: William L Bigbee: Innovator in Monoclonal Antibody Production
Introduction
William L Bigbee is a notable inventor based in Livermore, CA (US). He has made significant contributions to the field of biotechnology, particularly in the production of monoclonal antibodies. With a total of 3 patents, his work has the potential to impact various medical applications.
Latest Patents
One of his latest patents involves the development of cell lines for the production of monoclonal antibodies to human glycophorin A. Cloned mouse hybridoma cell lines have been established that continuously produce antibodies differentiating between the M and N forms of human glycophorin A. These antibodies have potential applications as human blood group reagents, markers for terminally differentiated erythroid cells, and as immunofluorescent labels of somatically variant human erythrocytes. Another patent focuses on monoclonal antibodies to human glycophorin A, where cloned mouse hybridoma cell lines have been established that continuously produce antibodies that are highly specific and exhibit high affinity for glycophorin A.sup.N, differentiating between the M and N forms of human glycophorin A.
Career Highlights
William L Bigbee has had a distinguished career, contributing to advancements in biotechnology and immunology. His innovative work has led to the establishment of important methodologies in the production of monoclonal antibodies.
Collaborations
He has collaborated with notable coworkers such as Ronald H Jensen and Martin Vanderlaan, further enhancing the impact of his research and inventions.
Conclusion
William L Bigbee's contributions to the field of monoclonal antibody production exemplify the importance of innovation in biotechnology. His patents and collaborative efforts continue to pave the way for advancements in medical applications.